First-Ever IL-23 Inhibitor: J&J's TREMFYA Approved for Children with Psoriasis, Shows 56% Clearance Rate

FDA Approves IL-23 Inhibitor for Pediatric Psoriasis and Psoriatic Arthritis

The approval was based on the PROTOSTAR study, which showed pediatric patients receiving the treatment achieved high levels of skin clearance versus placebo at week 16. The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Tremfya (guselkumab) for treating children six years and older with moderate to severe plaque psoriasis or active psoriatic arthritis. The approval makes Tremfya the first interleukin-23 (IL-23) inhibitor …

J&J gets FDA approval for Tremfya in paediatric psoriasis - Pharmaceutical Technology

Johnson & Johnson's Tremfya is the first IL-23 inhibitor to gain FDA approval in a paediatric population for plaque psoriasis.

FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis | Pharmacy Times - Pharmacy Practice News and Expert Insights

The FDA approves guselkumab, the first IL-23 inhibitor for pediatric psoriasis and psoriatic arthritis, enhancing treatment options for children.

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Psoriatic Arthritis | Dermatology Times - Dermatology News and Clinical Insights

Phase 3 PROTOSTAR data support new indications, expanding treatment options for children impacted by chronic immune-mediated diseases.

U.S. FDA Approves TREMFYA® (guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis, Marking a First and Only Approval for an IL-23 Inhibitor - Life Sciences British Columbia

HORSHAM, PA – Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab).

FDA Approves Guselkumab for the Treatment of Pediatric Plaque Psoriasis, Psoriatic Arthritis

This marks the first and only IL-23 approval for these indications in pediatric populations.